Figure 1

Pro-coagulant activation of human monocytes by fibrinogen. To test the ability of human fibrinogen to accelaerate monocyte coagulation, cells were pre-exposed to Haemocomplettan^®, a plasma-derived fibrinogen concentrate in clinical use, (left panel) or to a commercially available fibrinogen from Haematological Technologies Inc (right panel). Both products led to a comparable inhibition of the clotting time at concentrations as low as 2 mg/mL. As endotoxin is known to induce monocyte coagulation it served as positive control. PMCs and monocytes were used for the left panel, monocytes were used in the experiments on the right panel. Normalized results are given as mean ± SEM, n = 6. Time to clot formation of control monocytes (RPMI 1640 treated) was 360 ± 46.7 sec. Statistics were calculated using Kruskal Wallis and Mann Whitney U test. *: p < 0.05.